Vaccines - The Fastest Way Out of the Pandemic?

[Mary Wilson]

Jul 15, 2020
SETH BERKLEY, RICHARD HATCHETT, SOUMYA SWAMINATHAN

During the 2009 swine flu pandemic, a few countries cornered the vaccine market, leaving the vast majority of the global population with no vaccine at all until the outbreak was effectively over. This scenario must be avoided at all costs during the current crisis – and, thanks to the COVID-19 Vaccine Global Access Facility, it can be.

GENEVA – Every day, the COVID-19 pandemic costs the world thousands more lives and billions more dollars. The most efficient way to bring this crisis to an end – possibly as early as next year – is with a safe and effective vaccine, manufactured in large quantities and distributed globally. To avoid any unnecessary delays, governments should take this moment, while researchers work to develop the right formula, to prepare the ground for rapid production and broad, equitable deployment.

This is the principle on which the COVID-19 Vaccine Global Access (COVAX) Facility is based. Created by Gavi, the Vaccine Alliance, the World Health Organization, and the Coalition for Epidemic Preparedness Innovations, this innovative platform aims to distribute at least two billion doses of COVID-19 vaccine by the end of 2021.

https://www.project-syndicate.org/co...-et-al-2020-07

 

[Mary Wilson]

Stevanato Group Signs an Agreement With the Coalition for Epidemic Preparedness Innovations (CEPI) to Provide Pharma Glass Vials for 2 Billion Doses of COVID-19 Vaccines Under Development

Published: Jun 25, 2020

With this supply, Stevanato Group is playing a key role in the global challenge of scaling up the industrialization of glass vials, a critical component for the delivery of the vaccine

PIOMBINO DESE, Italy, June 25, 2020 /PRNewswire/ -- Italy-based Stevanato Group, a leading producer of pharmaceutical glass containers and integrated provider of drug delivery systems, and CEPI (the Coalition for Epidemic Preparedness Innovations) - the global partnership at the forefront of funding and coordinating the development of COVID-19 vaccine candidates - signed an agreement for the supply of 100 million Type 1 Borosilicate glass vials to hold up to 2 billion doses of a vaccine against the COVID-19 virus, should product(s) be proven safe and effective. This supply is part of CEPI's efforts to rapidly speed up the vaccine development timeline through making progress on manufacturing in parallel with the clinical development of COVID-19 candidate vaccines.

https://www.biospace.com/article/re...doses-of-covid-19-vaccines-under-development/